|
Gene: FAM65A |
Gene summary for FAM65A |
Gene summary. |
Gene information | Species | Human | Gene symbol | FAM65A | Gene ID | 79567 |
Gene name | RHO family interacting cell polarization regulator 1 | |
Gene Alias | FAM65A | |
Cytomap | 16q22.1 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q6ZS17 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79567 | FAM65A | P1T-E | Human | Esophagus | ESCC | 1.78e-14 | 5.52e-01 | 0.0875 |
79567 | FAM65A | P2T-E | Human | Esophagus | ESCC | 9.84e-09 | 9.96e-02 | 0.1177 |
79567 | FAM65A | P4T-E | Human | Esophagus | ESCC | 1.43e-10 | 1.47e-01 | 0.1323 |
79567 | FAM65A | P5T-E | Human | Esophagus | ESCC | 8.23e-06 | 1.11e-02 | 0.1327 |
79567 | FAM65A | P8T-E | Human | Esophagus | ESCC | 5.54e-18 | 2.45e-01 | 0.0889 |
79567 | FAM65A | P9T-E | Human | Esophagus | ESCC | 1.25e-03 | 1.33e-01 | 0.1131 |
79567 | FAM65A | P11T-E | Human | Esophagus | ESCC | 3.22e-08 | 2.73e-01 | 0.1426 |
79567 | FAM65A | P12T-E | Human | Esophagus | ESCC | 1.69e-08 | 1.17e-01 | 0.1122 |
79567 | FAM65A | P15T-E | Human | Esophagus | ESCC | 6.52e-08 | 1.41e-01 | 0.1149 |
79567 | FAM65A | P16T-E | Human | Esophagus | ESCC | 3.91e-08 | 1.05e-01 | 0.1153 |
79567 | FAM65A | P17T-E | Human | Esophagus | ESCC | 1.03e-05 | 1.92e-01 | 0.1278 |
79567 | FAM65A | P19T-E | Human | Esophagus | ESCC | 4.03e-04 | 3.13e-01 | 0.1662 |
79567 | FAM65A | P20T-E | Human | Esophagus | ESCC | 1.30e-08 | 7.15e-02 | 0.1124 |
79567 | FAM65A | P21T-E | Human | Esophagus | ESCC | 4.05e-11 | 2.94e-01 | 0.1617 |
79567 | FAM65A | P22T-E | Human | Esophagus | ESCC | 4.19e-11 | 1.83e-01 | 0.1236 |
79567 | FAM65A | P23T-E | Human | Esophagus | ESCC | 9.73e-17 | 2.75e-01 | 0.108 |
79567 | FAM65A | P24T-E | Human | Esophagus | ESCC | 1.74e-07 | 2.08e-01 | 0.1287 |
79567 | FAM65A | P26T-E | Human | Esophagus | ESCC | 1.40e-11 | 1.64e-01 | 0.1276 |
79567 | FAM65A | P28T-E | Human | Esophagus | ESCC | 1.05e-10 | 2.19e-01 | 0.1149 |
79567 | FAM65A | P30T-E | Human | Esophagus | ESCC | 3.83e-11 | 2.44e-01 | 0.137 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | |
Oral cavity | LP | |
Oral cavity | EOLP | |
Oral cavity | NEOLP | |
Esophagus | HGIN |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FAM65A | SNV | Missense_Mutation | rs751513185 | c.3413N>A | p.Arg1138Gln | p.R1138Q | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A7-A426-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD | |
FAM65A | SNV | Missense_Mutation | c.1232N>T | p.Ser411Leu | p.S411L | protein_coding | deleterious(0) | possibly_damaging(0.831) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | ||
FAM65A | SNV | Missense_Mutation | c.948N>T | p.Gln316His | p.Q316H | protein_coding | deleterious(0) | probably_damaging(0.956) | TCGA-AR-A251-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | ||
FAM65A | SNV | Missense_Mutation | novel | c.2990N>A | p.Arg997Lys | p.R997K | protein_coding | tolerated(0.43) | benign(0.028) | TCGA-B6-A400-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
FAM65A | SNV | Missense_Mutation | c.2503N>C | p.Glu835Gln | p.E835Q | protein_coding | deleterious(0.01) | probably_damaging(0.993) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | ||
FAM65A | SNV | Missense_Mutation | c.2692N>A | p.Asp898Asn | p.D898N | protein_coding | tolerated(0.11) | benign(0.014) | TCGA-C8-A1HM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | CR | ||
FAM65A | SNV | Missense_Mutation | rs137895953 | c.2951G>A | p.Arg984Gln | p.R984Q | protein_coding | tolerated(0.21) | possibly_damaging(0.548) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
FAM65A | insertion | Frame_Shift_Ins | novel | c.2007_2008insAGGG | p.Leu670ArgfsTer54 | p.L670Rfs*54 | protein_coding | TCGA-E9-A1NI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | |||
FAM65A | SNV | Missense_Mutation | rs745477264 | c.2783G>A | p.Arg928His | p.R928H | protein_coding | tolerated(0.32) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
FAM65A | SNV | Missense_Mutation | novel | c.1823N>T | p.Thr608Ile | p.T608I | protein_coding | tolerated(0.15) | benign(0) | TCGA-A6-2684-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |